Oxford BioTherapeutics enters into a strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer

CAR-T Digest - August 2020

Weekly Digest - December 2025

10 December 2025: Oxford BioTherapeutics enters into a strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer

Oxford BioTherapeutics (OBT) and GSK have entered a multi-year collaboration to discover new ADC-based cancer therapies
The partnership centers on OBT’s OGAP-Verify platform, which pinpoints high-value oncology targets suited for differentiated ADC development
OBT will identify and validate these targets, after which GSK will advance them through research, clinical development, and commercialization
OBT receives an upfront payment and remains eligible for milestones and royalties tied to progress and product success
Together, both companies aim to expand the reach of ADCs by unlocking novel targets that could bring this powerful modality to more cancer patients